Quarterly report pursuant to Section 13 or 15(d)

2. Liquidity and Financial Condition (Details Narrative)

v3.20.2
2. Liquidity and Financial Condition (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 24, 2020
May 02, 2020
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2020
Net income     $ 120,000   $ (1,203,000) $ 360,000 $ (488,000)  
Accumulated deficit     (171,886,000)     (171,886,000)   $ (172,246,000)
Working capital     11,698,000     11,698,000   $ 7,518,000
Cash received from sale of Micromed           610,000    
Several Investors [Member]                
Proceeds from exercise of warrants       $ 1,490,000        
Employees and Consultants [Member]                
Proceeds from exercise of stock options     $ 429,000          
Asset Purchase Agreement [Member]                
Aggregate sale price of Micromed division $ 850,000              
Cash received from sale of Micromed 610,000              
Credit received for future testing services from sale of Micromed 100,000              
Sale of assets, amount held in escrow 60,000              
Accounts receivable remaining from sale of asset $ 81,000              
Paycheck Protection Program [Member] | States Bank in Atlanta [Member]                
Proceeds from loan   $ 1,310,000       $ 1,310,000    
Loan interest rate   1.00%       1.00%    
Loan maturity date   Apr. 29, 2022       Apr. 29, 2022